0001181431-15-008178.txt : 20150611 0001181431-15-008178.hdr.sgml : 20150611 20150611182155 ACCESSION NUMBER: 0001181431-15-008178 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150609 FILED AS OF DATE: 20150611 DATE AS OF CHANGE: 20150611 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avalanche Biotechnologies, Inc. CENTRAL INDEX KEY: 0001501756 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 205258327 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1035 O?BRIEN DRIVE, SUITE A CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-272-6269 MAIL ADDRESS: STREET 1: 1035 O?BRIEN DRIVE, SUITE A CITY: MENLO PARK STATE: CA ZIP: 94025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blumenkranz Mark S. CENTRAL INDEX KEY: 0001614869 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36579 FILM NUMBER: 15927039 MAIL ADDRESS: STREET 1: C/O AVALANCHE BIOTECHNOLOGIES, INC. STREET 2: 1035 O'BRIEN DRIVE, SUITE A CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 rrd425656.xml X0306 4 2015-06-09 0 0001501756 Avalanche Biotechnologies, Inc. [AAVL] 0001614869 Blumenkranz Mark S. C/O AVALANCHE BIOTECHNOLOGIES, INC. 1035 O'BRIEN DRIVE, SUITE A MENLO PARK CA 94025 1 0 0 0 Common Stock 2015-06-09 4 S 0 15300 35.5200 D 532689 D Common Stock 2015-06-09 4 S 0 7000 36.2003 D 525689 D Common Stock 2015-06-09 4 S 0 200 37.3500 D 525489 D Common Stock 2015-06-10 4 S 0 600 39.9133 D 524889 D Common Stock 10531 I See Footnote Common Stock 10531 I See Footnote Common Stock 10531 I See Footnote Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. This transaction was executed in multiple trades in prices ranging from $35.0450 to $36.0400, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $36.0500 to $37.0000, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $37.2200 to $37.4800, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $39.9000 to $39.9800, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The shares are held directly by the Carla Helene Blumenkranz Irrevocable Trust. The shares are held directly by the Erik Davis Blumenkranz Irrevocable Trust. The shares are held directly by the Scott Aubrey Blumenkranz Irrevocable Trust. /s/ Michael Swartzburg, Attorney-in-Fact for Mark S. Blumenkranz 2015-06-11